News Blog
Staying Connected
-
Control Bionics Announces Reseller Agreement with DNR Wheels Pte Limited
Control Bionics has entered into a reseller agreement with DNR Wheels Pte Limited, a leading distributor in Singapore of mobility, homecare and rehabilitation equipment and technology. Read the Press Release.
-
Noah Callan, Kids+ AAC and Tech Coordinator, Reviews the NeuroNode Trilogy
The Kids+ Foundation provides specialist physiotherapy, occupational therapy and speech pathology services to kids in Australia, and their AAC and Tech Coordinator, Noah Callan, used the NeuroNode Trilogy and reviewed the system in a video.
-
Funding Made Easy: 3 Steps to Getting a Device
The first question we often get is “how much is a Control Bionics device?” We understand why: our technology has three powerful access methods and provides a lifetime solution for those with paralysis and loss of speech, so you might think it comes with a hefty price tag. The good news is that Control Bionics…
-
Control Bionics has “Fascinating Technology” According to NPR’s Cool Science Radio
Control Bionics CTO, James Schorey, and Sales Director, Meagan Koeneman, talked to NPR’s Cool Science Radio about the technology behind the NeuroNode Trilogy, who benefits from these products, and the importance of communication at the human level.
-
Popular Podcast, Fear and Greed, Spoke to Control Bionics on Their Sunday Feature
Control Bionics CEO Rob Wong sat down with the podcast Fear and Greed this week to discuss how Control Bionics helps patients with some of the most debilitating conditions to communicate.
-
Biotech Daily features Control Bionics in Dr. Boreham’s Crucible Article
As a regular contributor of Biotech Daily, which provides news on ASX-listed biotechnology companies, Dr. Boreham’s Crucible provides analysis of the biotech sector in Australia. Last week Control Bionics was featured in an article on the site.
-
Control Bionics (ASX:CBL) Looks to Solidify Global Presence
Rob Wong, CEO of Control Bionics, chats with Alan Kohler from Eureka Report to discuss the latest news from the newly ASX-listed business. ” … the fundamental point about that was that your brain sends very, very fast signals to muscles to act because that’s the fight or flight mechanism. Most of the outcomes that…
-
Control Bionics (ASX:CBL) Partners with Numotion as Northeastern US Reseller of Assistive Technology Solutions
Control Bionics, a global assistive technology company specializing in speech generating devices, announced it is partnering with Numotion, a leading provider of Complex Rehab Technology (CRT) to offer the Control Bionics’ Trilogy product line.
-
Control Bionics set to enter the ASX bourse next week; inspired by Stephen Hawking and already FDA approved
Medtech company Control Bionics (ASX:CBL) will list on the ASX next week. The company’s EMG (electromyography)-based technology helps people with disabilities inhibiting communications to do so through electronic devices that pick up their neuroelectric systems. Examples of such conditions include motor-neuron disease, cerebral palsy, and spinal cord injuries. Control Bionics’ flagship product, NeuroNode 3, is watch-sized…
-
Control Bionics Launches Latest Product Extension
Control Bionics announces the newest addition to its Augmentative and Alternative Communication (AAC) device line, the GridPad Trilogy™ communication solution. The new neuro-based voice output communication aid is intended to help people living with paralysis and loss of speech find their voice.
-
Opening Back Up In-Person Assessments
As we’ve globally transitioned into telepresence communication, we will still be offering our remote assessments alongside our industry-leading customer support. We understand that some communication needs, and assessments, may be challenging to support remotely and we are pleased to be opening back up in-person meetings and assessments.
-
Spectacular
Peter Ford remembers Michael Phillips from a decade of emails and text messages about AT code and evolving technology, the nature of existence, and the writers whom they admired.